EXPERIMENTAL THERAPY

US FDA declines to approve Ascendis' hormone disorder therapy

Ascendis' US-listed shares rose 12 per cent in premarket trade. The FDA, early last month, had identified unspecified deficiencies in the company's application for approval of the therapy, TransCon PTH. TD Cowen analyst Yaron Werber had raised concerns about the lack of clarity around FDA's decision in a note on Friday.